LLY compared with ABUS: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

ABUSArbutus Biopharma Corp

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

ABUSArbutus Biopharma Corp

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

LLYELI Lilly & Co

1,418.01· pre 1,399.63· delayed

Mkt cap$1.3TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

ABUSArbutus Biopharma Corp

4.01· pre 4.28· delayed

Pre-marketNov 3 '26delayed

Mkt cap$791.4MRevenue$1MQ2 FY26Revenue$14MFY25

Compare

Pre-marketNov 3 '26delayed

LLYELI Lilly & Co

ABUSArbutus Biopharma Corp

1,418.01pre 1,399.63delayed

Price

4.01pre 4.28delayed

$1.3T

Mkt cap

$791.4M

Q3 FY26$24.4B

Revenue

$1MQ2 FY26

FY25$65.2B

Revenue

$14MFY25

LLY1,418.01vsABUS4.01Pre-marketNov 3 '26delayed

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

ABUS: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only LLY 29

MCKMcKessoncustomer

CAHCardinal Healthcustomer

VEEVVeeva Systemssupplier

UTHRUnited Therapeuticscustomer

25 more · LLY chain ›

Shared 0

No shared counterparties.

Only ABUS 9

MRNAModernacustomer

ALNYAlnylam Pharmaceuticalscustomer

ASMBAssembly Biosciencessupplier

—Qilu Pharmaceuticalunlisted

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

customer

5 more · ABUS chain ›

Price

rebased to 0%

LLY, solidABUS, dashed